Recently published research results:
- A preliminary patient-reported outcomes analysis of high-dose 3D-CRT vs IMRT for intermediate-risk prostate cancer show no differences in outcomes between the two modalities.
- The survival benefit of intraperitoneal vs intravenous chemotherapy in women with advanced ovarian cancer extends beyond 10 years.
The phase II NRG-GY001 trial activates to evaluate the anti-tumor activity of cabozantinib (XL184) in women with persistent or recurrent clear cell ovarian cancer. Read more
NRG-CC002, the first NRG NCORP-sponsored trial, launches to evaluate an assessment tool to gain insight about outcomes in elderly women undergoing treatment for gynecologic cancers Read more
Merry-Jennifer Markham, MD, a member of the NRG Oncology Social Media Subcommittee, was profiled in the Feb 10 issue of Oncology Times. Read more
Image-guided radiotherapy reduces long-term treatment side effects in patients with soft tissue sarcoma. Read more
In patients with advanced ovarian cancer, the extent of disease at initial diagnosis is a significant prognostic indicator with the level of surgery complexity found not to affect progression-free survival or overall survival. Read more
NSABP B-31 and NCCTG N9831 article named one of top 8 articles downloaded from JCO website in 2014. Read more
Higher-dose radiotherapy results in inferior survival in patients with stage III lung cancer. Read more